Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.
GSK plc has announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B common stock of Nuvalent, Inc. The announcement references an Agreement and Plan of Merger dated June 9, 2026 between GlaxoSmithKline LLC, Harmony Row Acquisition Co. and Nuvalent.
The communication is a pre-commencement Schedule TO filing and states the tender offer has not yet commenced. When the offer is launched, GSK plc, Parent and Purchaser will file a Tender Offer Statement on Schedule TO and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9.
GSK plc plans to acquire US oncology company Nuvalent, Inc. in a cash deal valuing the target at $10.6 billion. GSK will launch a tender offer at $124 per share, a 40% premium to Nuvalent’s last closing price and 26% above its 30‑day VWAP.
The transaction adds three lung cancer drugs, including two late‑stage ROS1 and ALK inhibitors under US FDA review with 2026 target decision dates, plus a HER2 inhibitor in phase I. GSK expects low single‑digit core EPS dilution through 2028, accretion to core operating profit in 2027 and to core EPS in 2029, while maintaining 2026 guidance and a 70p dividend.
GSK plc reports further repurchases of its ordinary shares between 1 and 5 June 2026 as part of its existing buyback programme, executed through Citigroup Global Markets Limited. Daily buybacks ranged from 217,096 to 496,356 shares, with volume-weighted average prices between 1,824.85 GBp and 1,922.23 GBp per share.
Since 11 May 2026 the company has purchased 6,233,812 ordinary shares. After the latest transactions, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue, giving the same number of total voting rights. Treasury shares represent 6.61% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reported its total voting rights as of 31 May 2026. The company’s issued share capital consisted of 4,316,224,814 ordinary shares of 31 ¼ pence each, of which 265,968,706 were held in treasury. This leaves 4,050,256,108 voting rights currently in issue.
Shareholders can use this voting rights figure as the denominator when calculating whether they must notify the company and regulators about their shareholdings or changes in their interests under the UK Financial Conduct Authority’s disclosure rules.
GSK plc reports that, under its existing share buyback programme, it repurchased ordinary shares of 31¼ pence each on 26–29 May 2026 through Citigroup Global Markets Limited. Daily purchases ranged from 301,200 to 319,949 shares, at volume weighted average prices between 1,899.95 and 1,932.82 GBp per share.
The repurchased shares will be held as treasury shares. Since 11 May 2026 the company has bought 4,590,420 ordinary shares. After these transactions, GSK holds 265,968,706 ordinary shares in treasury and has 4,050,256,108 ordinary shares in issue, which is also the total number of voting rights, with 6.57 per cent of voting rights attributable to treasury shares.
GSK reports pivotal Phase III results showing its investigational hepatitis B therapy bepirovirsen achieved markedly higher functional cure rates than current treatments. In pooled B‑Well 1 and 2 trials, 6‑month bepirovirsen plus standard of care produced a 19% functional cure in adults with baseline HBsAg ≤3000 IU/mL, versus 0% with standard care alone.
Among participants with baseline HBsAg ≤1000 IU/mL, who represent a large share of diagnosed cases, the functional cure rate reached 26% versus 0% on placebo. An exploratory analysis found 49% of bepirovirsen recipients had qHBsAg ≤100 IU/mL one year after treatment ended, a level associated with stronger immune control.
Bepirovirsen also delivered sustained HBV DNA suppression in 23% of all treated participants and 31% of those starting with HBsAg ≤1000 IU/mL, with safety generally characterized by injection‑site reactions and transient liver enzyme elevations. The drug is under priority review in the US and other major markets, with first regulatory decisions expected in Q3 2026.
GSK plc reported an insider transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) through her GSK Executive Supplemental Savings Plan account. The plan credited 9.293 ADS at a price of $51.3800 per ADS on May 22, 2026, with the transaction executed on the New York Stock Exchange.
GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.
GSK plc reports that, under its existing share buyback programme and a non-discretionary agreement with Citigroup Global Markets Limited, it repurchased ordinary shares on the London market between 18 and 22 May 2026.
On those dates, GSK bought between about 329,000 and 339,000 shares per day at volume‑weighted average prices ranging from 1,867.02 GBp to 1,918.46 GBp. Since 11 May 2026, the company has repurchased 3,342,149 ordinary shares, which are being held as treasury shares.
After these purchases, GSK holds 264,720,435 ordinary shares in treasury and has 4,051,501,116 ordinary shares in issue excluding treasury. The total number of voting rights is 4,051,501,116, and GSK states that treasury shares represent 6.53% of voting rights for regulatory disclosure calculations.